Toll-interacting protein polymorphisms in viral bronchiolitis outcomes

dc.contributor.authorTärmänen Sari
dc.contributor.authorTeräsjarvi Johanna
dc.contributor.authorNuolivirta Kirsi
dc.contributor.authorHe Qiushui
dc.contributor.authorKorppi Matti
dc.contributor.authorLauhkonen Eero
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.converis.publication-id66651735
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/66651735
dc.date.accessioned2022-10-27T11:52:33Z
dc.date.available2022-10-27T11:52:33Z
dc.description.abstractBackground Toll-interacting protein is a key factor in regulating innate immunity responses via gatekeeping Toll-like receptors. Genetic variance in innate immunity has been linked with susceptibility to infections. Children with viral bronchiolitis in infancy are at increased risk of later asthma. The aim was to evaluate the role of toll-interacting protein gene point mutations in severity of bronchiolitis and subsequent risk of asthma. Methods Infants less than 6 months old were recruited during hospitalization due to bronchiolitis. In all, 166 children were prospectively followed up to age of 1.5, 6, and 11 years. Clinical data on viral etiology and severity markers, and further post-bronchiolitis asthma and lung function outcomes were compared with genetic differences in two single-nucleotide point mutations rs116938768 and rs5743854 in the toll-interacting protein gene. Results Toll-interacting protein rs116938768 or rs5743854 did not show significant associations with severity markers or viral etiology of bronchiolitis. Follow-up data on current asthma or lung function at 6 or 11 years of age after bronchiolitis were not associated with the investigated mutations. Conclusion Toll-interacting protein gene point mutations in rs116938768 or rs5743854 were not involved with the clinical course of viral bronchiolitis in early infancy, and did not predict post-bronchiolitis asthma or lung function reduction by the age of 11 years.
dc.identifier.jour-issn1328-8067
dc.identifier.olddbid172475
dc.identifier.oldhandle10024/155569
dc.identifier.urihttps://www.utupub.fi/handle/11111/30213
dc.identifier.urlhttps://doi.org/10.1051/0004-6361/202039633
dc.identifier.urnURN:NBN:fi-fe2021093047944
dc.language.isoen
dc.okm.affiliatedauthorTeräsjärvi, Johanna
dc.okm.affiliatedauthorHe, Qiushui
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherWILEY
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.doi10.1111/ped.14746
dc.relation.ispartofjournalPediatrics International
dc.relation.issue9
dc.relation.volume63
dc.source.identifierhttps://www.utupub.fi/handle/10024/155569
dc.titleToll-interacting protein polymorphisms in viral bronchiolitis outcomes
dc.year.issued2021

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
ped.14746.pdf
Size:
127.83 KB
Format:
Adobe Portable Document Format
Description:
Publisher's pdf